During the COVID-19 pandemic, a correspondence, published at the Lancet Respiratory Medicine, that linked angiotensinconverting enzyme inhibitors, angiotensin receptor blockers and ibuprofen to a higher risk of SARS CoV-2 infection and complications, has influenced, when adopted by official health authorities, the practical management of COVID-19 with regard to non-steroidal anti-inflammatory drugs that were avoided in all COVID-19 management protocols all over the world. This manuscript discusses, from a pharmacological point of view, the points of weakness in the mentioned correspondence and it also lists some important contradictory review articles as well as clinical results that refuted its claims. The author chose to argue against each claim represented in the mentioned correspondence to confirm that ACEIs, ARBs and NSAIDs including ibuprofen should not be considered hazardous to be administered for COVID-19 patients and to warn against any future adoption of such unproved claims. Keywords COVID-19 • SARS CoV-2 • Aceis • Arbs • Ibuprofen Abbreviations ACEIs Angiotensin-converting enzyme inhibitors ARBs Angiotensin receptor blockers SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 COVID-19 Coronavirus disease 2019 D. Rainsford; Editor in Chief and Dr. Phil Berry; Deputy Editor of Inflammopharmacology for their highly valuable remarks as well as their timely and highly professional management of this manuscript. The author has tried since March 2020 to publish the main body of this manuscript and only on June 2020 a preprint has been published after a dozen of rejections without peer review (Kelleni M 2020, June 2,) and only Inflammopharmacology has accepted to peer review it. Funding None.